tbuckley/cabot-search huggingface dataset:
The effect of tai chi chuan on bone remodeling and cytokines among breast cancer survivors: A feasibility trial
Authors: L. J. Peppone, K. Mustian, R. N. Rosier, K. M. Piazza, D. G. Hicks, O. G. Palesh, T. V. Darling, J. Q. Purnell, M. Janelsins, G. R. Morrow
Journal: Journal of Clinical Oncology (2009)

9610 Background: Weight-bearing exercise may slow the rate of bone loss associated with breast cancer treatment. The purpose of this study is to determine the effect of tai chi chuan (TCC) on bone health, as measured by the changes in the levels of bone resorption and bone formation. This study also aimed to investigate whether changes in bone health were correlated with growth and inflammation markers that serve as regulators of bone cell function. Methods: Female patients (N=16) who completed treatment for breast cancer within the past 30 months were randomly assigned to either the TCC group or the psycho-educational support group without exercise (ST) for 60 minutes, three times a week for a period of 12 weeks. Serum levels of bone resorption (N-telopeptides of type I collagen; NTx) and bone formation (bone specific alkaline phosphatase; BAP) were determined by ELISA at baseline and post-intervention. Using validated methods, a bone remodeling index (BRI) was calculated from levels of NTx and BAP. In addition, pre- and post-intervention levels of insulin-like growth factor binding protein 1 (IGFBP-1) and interleukin-2 (IL-2), markers associated with excessive bone resorption, were measured. Lastly, levels of interleukin-6 (IL-6), believed to enhance bone formation, were measured at both pre- and post-intervention. Results: ANCOVA analyses demonstrated that survivors in the TCC group experienced a greater increase in bone remodeling than those in the ST group (Δ BRI TCC =1.6 vs Δ BRI ST =0.2; p=0.04). All correlations were determined by Pearson's correlation coefficients. IGFBP-1 was negatively correlated with increasing bone remodeling levels (r=-0.43, p=0.14). IL-2 was also negatively correlated with increasing bone remodeling levels (r=-0.35, p=0.24). IL-6 was positively correlated with increasing bone remodeling levels (r=0.69, p=0.01). Conclusions: This pilot study suggests that TCC has positive effects on bone remodeling through changes in growth and inflammation factors that regulate bone cell function. A larger, more definitive trial examining the influence of TCC on bone remodeling is warranted. Funding: Sally Schindel Cone and R25 CA102618 No significant financial relationships to disclose.
THE METABOLISM OF ADRENALINE
Authors: Z. M. Bacq
Journal: Pharmacological Reviews (1949)

The statement formulated in 1905 by Elliott (5) that adrenalin disappears in the tissues which it excites is unquestionable. Review of the literature shows 1) that adrenaline may be excreted unchanged in small amounts by the kidneys and stored in the tissues and red blood cells; 2) that its deamination by amineoxidase in the body is unlikely; 3) that an important fraction is sulfoconjugated; 4) that another important fraction is simultaneously oxidized to indole substance; 5) that adrenochrome and its derivatives have important biochemical and physiological properties, entirely different from those of adrenaline, and deserve further study.
Abstract 15132: Peripheral Endothelial Dysfunction is a Significant Determinant of Contrast-Induced Renal Damage in Patients Underwent Percutaneous Coronary Procedures
Authors: Hitoshi Sumida, Yasushi Matsuzawa, Seigo Sugiyama, Eiichi Akiyama, Satomi Iwashita, Hisao Ogawa
Journal: Circulation (2011)

Background. Procedure-related and contrast-induced renal damage (PCRD) is an important complication of coronary angiography and percutaneous coronary interventions associated with poor cardiovascul...
Abstract 17704: The Association of Tooth Scaling and Decreased Cardiovascular Disease -A Nationwide Population-Based Study
Authors: Zu-Yin Chen, Hsin-Bang Leu
Journal: Circulation (2011)

Background: Poor oral hygiene has been associated with increased risk for cardiovascular disease frequent tooth brushing has been reported to decrease the risk for CVD recently. However, the association between preventive dentistry and cardiovascular risk reduction remained undetermined. The aim of this study is investigate the effect of mouth scaling on cardiovascular disease and stroke risk, using a nationwide, population-based study and a retrospective cohort design. Methods: 51108 adult subjects without previous history of stroke or myocardial infarction (MI) who had received full or partial mouth scaling at least once were rerolled from the Taiwan National Health insurance. Another 51512 age-, gender-, and cormobidities-matched subjects without history of stroke or MI and did not receive mouth scaling comprised the comparison control. Cox proportional hazard regressions were performed as a means of comparing the cardiovascular events rate between these two cohorts. Results: During an average follow-up period of 7 years, a total of 102,620 patients were enrolled, of which 51,108 patients who had ever received tooth mouth scaling had lower incidence of acute MI and stroke when compared to the control group (0.55% vs. 0.44%, p=0,013 and 2.57% vs. 2.27%, p=0.002, respectively). The log-rank test and Kaplan-Meier survival analysis showed that patients with tooth scaling have significantly higher AMI- free and higher stroke-free survival rates ( p =0.027 and p= 0.04 respectively). Cox proportional hazard regression model analysis showed that tooth scaling was the independent factor associated with less risk of developing future MI (Hazard Ratio, HR, 0.76, 95% CI, 0.60-0.96; p =0.021) and stroke (HR 0.87, 95% CI, 0.78-0.96; p =0.007). Furthermore, the frequency of tooth scaling correlated with the risk reduction of MI with HR of 0.76 (95% CI, 0.60-0.96; p =0.021) and HR of 0.87 (95% CI, 0.71-1.07; p= 0.188), comparing often and occasional with never tooth scaling, respectively; stroke with HR 0.87, (95% CI, 0.78-0.96; p =0.007) and HR of 0.91 (95% CI, 0.83-1.00; p =0.045), comparing often and occasional with never tooth scaling, respectively. Conclusions: Tooth scaling was associated with decreased risk for cardiovascular risk and stroke.
Esophageal squamous cell carcinoma in the VA population: What is the optimal treatment modality
Authors: M. M. Safa, M. S. Beg, M. Atiq, S. Ali, R. Komrokji
Journal: Journal of Clinical Oncology (2007)

15042 Introduction: Surgery for esophageal squamous cell carcinoma (SCC) has been the mainstay of treatment despite dismal outcome and significant surgical complications. There is no standard treatment modality for esophageal SCC. Methods: The VA (veteran affairs) Central Cancer Registry (VACCR) is a function of the Chief, Program Office for Oncology at VA Headquarters in Washington DC. We queried the VACCR database for all diagnosed squamous cell esophageal cancer cases between 1995 and 2005 using ICD codes 150–159. The data was transformed, entered and analyzed using SPSS v.13.0. We analyzed, in a retrospective fashion, survival in VA patients with early disease (stages 1–2), and locally advanced (stage 3) SCC comparing the treatment modality: chemoradiation alone (CRT), surgical resection alone (SUR) or trimodality therapy (TMT) which includes all three treatment options. Results: Out of a total of 6874 patients diagnosed with esophageal carcinoma, 2894 patients had SCC. A total of 433 patients were included in this study that were staged as 1–3 and had complete treatment information available. Baseline characteristics were not different between the three groups and are summarized in table 1 . Out of those, 57 (13.2%) received SUR, 323 (74.6%) CRT, and 53 (12.2%) TMT. Kaplan Meier analysis for median survival in early disease was 14 mo for SUR, 17 mo in CR, and 79 mo in TMT (p = 0.0288). There was no difference in survival among patients with locally advanced disease between the treatment groups (p = 0.7079) Conclusion: In VA patients with early esophageal SCC, TMT confers better survival than SUR or CRT. However, in patients with advanced disease, SUR, CRT and TMT groups showed comparable outcome. [Table: see text] No significant financial relationships to disclose.
Prevalence and characteristics of hereditary nonpolyposis colon cancer (HNPCC) syndrome in immigrant Chinese cancer patients.
Authors: Y. Xiao, B. Clark, Y. Huang, M. I. Chorost, J. Li, N. Khulpateea, R. Lengvilas, R. Shen, Y. Xu
Journal: Journal of Clinical Oncology (2010)

e12019 Background: Hereditary nonpolyposis colon cancer (HNPCC) syndrome is a hereditary disorder that predisposes to colon, endometrial, and gastric cancers before 50 years old. Molecular diagnoses, by testing microsatellite instability (MSI), or immunohistochemical staining (IHC) of the lack of the mismatch repair (MMR) protein expression and genomic sequencing of the MMR genes, is more sensitive and specific than the clinical diagnostic criteria, such as Amsterdam or Bethesda criteria. HNPCC affects 2-5% of Caucasian population. We aim in this study to evaluate the prevalence and clinical characteristics of HNPCC in Chinese patients (immigrants) newly diagnosed of colon, endometrial, and gastric cancer. Methods: Patients of Chinese ethnicity diagnosed of colorectal, endometrial, or gastric cancer in Maimonides Medical Center from 2000 to 2009 were eligible and 150 cases were identified. Medical records were reviewed and IHC staining of four MMR genes, namely MLH1, MSH2, MSH6, and PMS2 were performed on primary tumor specimens. Results: Forty-nine cases were studied so far, 33 of colon cancer, 3 of endometrial cancer and 13 of gastric cancer. There were 24 males and 25 females, age ranges from 32 to 93 years old. Nine patients (4 colon cancers and 5 gastric cancers) were diagnosed at age younger than 50 years old, and none had deficiency of MMR expression by IHC. Two abnormal cases were detected as described below and were confirmed in Ohio State University. Conclusions: Colon cancer with suspected HNPCC MSH6 mutation can have first presentation in patients greater than 50 years old in Chinese patients. The prevalence and characteristics of HNPCC in Chinese patients warrants further study, which is still ongoing. Case Age Gender Cancer site Tumor grade and differentiation Family history IHC staining result and interpretation 1 66 M Ascending colon T2N0M0 adeno ca, moderately differentiated None MSH6 negative, suggestive of HNPCC 2 86 F Ascending colon T1N0M0 adeno ca, poorly differentiated, mucin production None MLH1, PMS2 negative, consistent with MLH1 hypermethylation No significant financial relationships to disclose.
18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma
Authors: Stefania Gori, Alessandro Inno, Gianluigi Lunardi, PharmD, Giancarlo Gorgoni, PharmD, Veronica Malfatti, Fabrizia Severi, Filippo Alongi, Giovanni Carbognin, Luigi Romano, Stefano Pasetto, Matteo Salgarello
Journal: Journal of Thoracic Oncology (2015)
A BCR-ABL Oncoprotein p210b2a2 Fusion Region Sequence Is Recognized by HLA-DR2a Restricted Cytotoxic T Lymphocytes and Presented by HLA-DR Matched Cells Transfected With an Iib2a2 Construct
Authors: George J.A. ten Bosch, Jan H. Kessler, Antonia M. Joosten, Alexandra A. Bres-Vloemans, Annemieke Geluk, Barbara C. Godthelp, Jeroen van Bergen, Cornelis J.M. Melief, Onno C. Leeksma
Journal: Blood (1999)
WDRPUH, a novel WD-repeat protein highly expressed in hepatocellular carcinoma, is involved in proliferation of cancer cells
Authors: Fabio Pittella Silva, Ryuji Hamamoto, Yusuke Nakamura, Yoichi Furukawa
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

2337 

Hepatocellular carcinoma (HCC) is one of the most prevalent and intractable cancers, causing as many as half million deaths per year worldwide. In an attempt to disclose mechanisms of hepatocarcinogenesis and discover novel target molecules for diagnosis and treatment of HCCs, we previously analyzed expression profiles of HCC tissues from a total of 20 HCC patients using a cDNA microarray containing 23040 genes. Among the genes up-regulated in more than 75% of tumor tissues compared with its non-tumor counterparts, we focused on a novel gene termed WDRPUH (WD40 repeat protein up-regulated in HCC) and characterized its biological function. Semi-quantitative RT-PCR confirmed its elevated expression in eight out of ten additional HCC tissues. WDRPUH encodes a predicted 620 amino acid protein containing 11 highly conserved WD40 repeat domains. Multiple-tissue northern blot analysis revealed its specific expression in the testis among the 16 normal tissues examined. Immunocytochemical staining of HCC cells transfected with plasmids expressing the tagged-WDRPUH protein demonstrated its subcellular localization in the cytoplasm. Colony formation assay revealed growth-promoting effect of WDRPUH in NIH3T3 cells, suggesting an oncogenic activity of WDRPUH. Consistently, transfection of plasmids designed to express WDRPUH-specific siRNA significantly reduced its expression in HepG2, Huh7, SNU449 and Alexander HCC cells, and resulted in growth suppression of the transfected cells. We further found that WDRPUH associated directly with HSP70, proteins of the chaperonin-containing TCP-1 (CCT) complex, and BRCA2. These findings have disclosed a novel insight into hepatocarcinogenesis. Since WDRPUH expression is enhanced in the majority of HCC tissues and its suppression lead to retarded growth of HCC cells, inhibition of WDRPUH may be an effective therapeutic option. In addition, because it is expressed in cancer tissues and testis and not in other normal tissues examined, WDRPUH may be useful for immunotherapy as a cancer-testis specific antigen. These data suggests that WDRPUH may be a good molecular target for the development of new anticancer drugs to HCCs.
Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study
Authors: J. Martin, A. Poveda, A. Llombart-Bosch, R. Ramos, J. García Del Muro, J. Martinez, A. De Juan, J. Maurel, F. Losa, J. M. Buesa
Journal: Journal of Clinical Oncology (2004)

9029 Background: Several studies of prognostic factors have been published in mesenchymal tumors of the gastrointestinal tract. Most of them, however, have not considered the current definition of GIST. In patients with complete surgical resection the size of primary tumor and the mitotic count seems to be the most predictive of disease-specific survival. The analysis of kit-mutation (level or type) has emerged as a potential prognostic significance in GIST patients, although, to date, the results remains controversials requiring a larger patient numbers or a more extensive mutational analysis of all exons known to be implicated in the KIT and PDGFRα gens. Methods: Three hundred and fifty patients with eventual GIST diagnosis included between 1994–2001 in our Registry and admitted in 29/53 hospitals members of GEIS were evaluated. The clinical collected data has been updated and a independent pathologic review of paraffin-embedded blocks including inmunohistochemistry with kit, s-100 protein, smooth muscle actin and desmin antibodies has been performed. According to our inclusion criteria (complete surgical resection, c-kit +, no metastasis at presentation, tumor size more than 2 cm and absence of second primary tumor) 165 patients were included in the present study. In this subset we have analized age, sex, tumor size, mitotic count (x50 hpf), location of GIST, necrosis, cellularity and predominant cell type . The mutational analysis including c-kit gen 9, 11, 13 and 17 exons and PDGFRα gen 12 and 18 exons is in process. Kaplan-Meier method and Cox proportional hazard model were used for statistical analysis. Results: Gender, tumor size (< 6 cm or >= 6cm), mitotic count (<5 or >= 5 ), location (stomach or small intestine) and cellularity (high or paucicellular) were prognostic factors for disease-free survival. In multivariate analysis high cellularity, mitotic count >= 5 and size >= 6 cm remained as poor independent prognostic factors. Conclusions: High cellularity, in addition to mitotic count and size, should be considered for the risk of recurrence in complete resected GIST patients. No significant financial relationships to disclose.
Medical care and treatment of allergic rhinitis: a population-based cohort study based on routine healthcare utilization data
Authors: J. Schmitt, E. Stadler, D. Küster, E. G. Wüstenberg
Journal: Allergy (2016)

Health services research on medical care and treatment of allergic rhinitis (AR) is scarce.To investigate the prevalence, incidence, comorbidities, and treatment of AR in a realistic setting.A cohort of 1 811 094 German National Health Insurance beneficiaries in 2005 was followed until 2011. To avoid misclassification, the ICD-10 code for AR (J30) had to be documented at least twice to classify patients as having AR. Descriptive statistics and logistic regression models were used to describe the burden, comorbidities, and treatment of AR.A total of 111 394 patients (6.2%) had prevalent AR in 2005/2006. In another 60 145 individuals (3.3%), AR was newly diagnosed in 2007 to 2011 (incident cases). Patients with prevalent AR were three times more likely to develop asthma compared to patients without AR (age and sex-adjusted risk ratio (RR) 3.04; 95% confidence interval (95%CI) 2.98-3.10). Newly diagnosed recurrent depressive disorder (RR 1.61; 95%CI 1.55-1.68), anxiety disorder (RR 1.52; 95%CI 1.48-1.56), and ADHD (RR 1.21; 95%CI 1.13-1.29) were also related to prevalent AR. Approximately 20% of children and 36% of adults with AR were exclusively treated by general practitioners. Allergy immunotherapy (AIT) was prescribed for 16.4% of patients with AR. Subcutaneous immunotherapy was most frequently used (80% of AIT).This study highlights the significant burden of AR. Despite the established benefits of AIT to treat AR and prevent asthma, this study suggests significant undertreatment. Future research is necessary to develop and implement adequate measures to increase guideline adherence.
Survival in high-grade osteosarcoma: Improvement in a 21-year period at a single institution
Authors: P. Picci, M. Mercuri, S. Ferrari, M. Alberghini, A. Briccoli, C. Ferrari, E. Pignotti, G. Bacci
Journal: Journal of Clinical Oncology (2009)

10515 Background: After the introduction of pre-operative chemotherapy in the early 1980s, treatment of osteosarcoma had not advantages from new drugs/modalities. Aim of this work is to analyze improvements in overall survival for patients treated over 21 years (1982–2002), with a 5-year minimum follow-up, in the largest series from a single institute ever reported, including all high grade osteosarcomas, despite histology varieties, age, site, and stage. Data are also analyzed in subgroups to define patients who benefited most. Methods: All diagnoses of high grade osteosarcoma were included. Of the 1,656 consecutive cases observed, 198 patients were excluded (41 consultation only, 129 low-grade varieties and 28 lost to follow-up). Within 1,456 included patients, 1,032 had characteristics to be enrolled in conventional clinical trials (classic histology, age &lt; 41, localized and extremity disease). Results: Considering all patients, with a median follow-up of 12 years (5–25 yrs), 754 (51.7%) are alive, 613 continuously disease-free. Survival at 5, 10, and 15 years is 57%, 52%, and 51% respectively. Patients candidates for clinical trials have a survival rate of 68%, 64%, and 61% respectively. Survival for the other patients is 30%, 25%, and 24% respectively. Jointpoint Statistical Analysis at real 5-year follow-up shows a yearly statistically significant improvement in survival of 1.31% (95% CI 0.5–2.1), from 51% for patients treated in 1982 to 68% for those treated in 2002. Within the subgroups, survival statistically improved in patients candidates to protocols, those who relapsed, or presented with metastatic disease at diagnosis, or had axial tumors. Surgery was also analyzed, with a statistical significant increase in the percentage of limb salvage procedures without an increased rate of local recurrences. Conclusions: Despite the lack of new drugs for osteosarcoma, survival has statistically improved, especially for those patients with the worst outcome. Aggressive treatments are therefore recommended for all patients including those with poor prognosis. No significant financial relationships to disclose.
Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs Role of glycoprotein IIB/IIIA receptors
Authors: L Molero
Journal: Cardiovascular Research (2002)

To assess whether endothelin-1 (ET-1) induces the in vivo expression of inflammatory-related proteins, namely cyclooxygenase-2 (COX-2) and tissue factor, in the myocardium and circulating leukocytes of guinea-pigs. The involvement of platelets was also analyzed.ET-1 (0.013 microg/min) was infused to male guinea-pigs for 45 min in the presence and absence of tirofiban, a nonpeptidic blocker of the glycoprotein IIb/IIIa receptor (GPIIb/IIIa). Tissue factor and COX-2 expression were determined by Western blot.No changes in mean arterial pressure and heart rate were detected. ET-1-infused guinea-pigs showed a marked increase in the number of platelets expressing activated GPIIb/IIIa receptors (0.8+/-0.03% vs. 6.5+/-0.2%; P<0.05). Tirofiban (10 microg/Kg bw/min) blunted ex vivo platelet aggregation in response to ADP, although only partially reduced COX-2 and tissue factor expression in both the myocardium and leukocytes of ET-1-infused guinea-pigs. The myocardium of platelet-depleted guinea-pigs also showed a reduced COX-2 expression after ET-1 infusion (57+/-3% reduction; P<0.05). In vitro studies demonstrated that platelets (10(7) and 10(9) platelets/well) enhanced ET-1 (10(-7) mol/l)-induced COX-2 expression in heart slices.ET-1 stimulated in vivo the expression of the pro-inflammatory proteins COX-2 and tissue factor in the myocardium and in leukocytes by a mechanism GPIIb/IIIa platelet receptors.
Penetrating Keratoplasty in South East London 1981–1986: Epidemiological Aspects and Demands on Medical Resources
Authors: C Claoué, M Falcon, J Shilling
Journal: Journal of the Royal Society of Medicine (1990)

We have compared penetrating keratoplasty at a teaching hospital and a district general hospital (DGH). At the teaching hospital, the pathology was similar to previous reports, but at the DGH the patients were older (P less than 0.01) and had a worse prognosis. The vision in the unoperated eye was also frequently poor. The number of postoperative outpatient visits within a hospital was unrelated to the original disease, and there was no statistically significant difference between the two centres. At the DGH, a corneal transplant patient requires the outpatient resources equivalent to three matched cataract patients. The implications for medical manpower requirements are discussed.
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.
Authors: S Cortelazzo, P Viero, G Finazzi, A D'Emilio, F Rodeghiero, T Barbui
Journal: Journal of Clinical Oncology (1990)

The purpose of this study was to determine which factors were associated with an increased risk of thrombo-hemorrhagic complications in a historical cohort of 100 consecutive and unselected patients with essential thrombocythemia (ET) in whom busulfan treatment was given when platelets were more than 1,000 x 10(9)/L and/or a major thrombotic or hemorrhagic event occurred. The incidence of major hemorrhagic complications was very low (0.33%/person-time at risk [pt-yr]) in comparison with that of thrombotic episodes (6.6%/pt-yr). In an adequate and appropriate control historical group of 200 patients, no severe hemorrhages were recorded and the incidence of thrombotic events was 1.2% pt-yr. Thus, the analysis of risk factors was restricted to this latter group of events. Age, a previous thrombotic event, and long duration of thrombocytosis were identified as major risk factors for thrombosis, while smoking, diabetes mellitus, hyperlipidemia, and hypertension did not influence the rate of thrombotic episodes.